D Belpomme

3.8k total citations
102 papers, 2.5k citations indexed

About

D Belpomme is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, D Belpomme has authored 102 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Pathology and Forensic Medicine and 17 papers in Genetics. Recurrent topics in D Belpomme's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (16 papers) and Acute Lymphoblastic Leukemia research (11 papers). D Belpomme is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (16 papers) and Acute Lymphoblastic Leukemia research (11 papers). D Belpomme collaborates with scholars based in France, United States and United Kingdom. D Belpomme's co-authors include Philippe Irigaray, Lennart Hardell, Richard Clapp, Luc Montagnier, G Mathé, J.A. Newby, C. V. Howard, Graham J. Kemp, John R. Lurain and Bernard Roullet and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

D Belpomme

95 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D Belpomme France 23 710 508 340 317 313 102 2.5k
J. K. McLaughlin United States 33 899 1.3× 472 0.9× 506 1.5× 861 2.7× 467 1.5× 58 4.1k
Eugene H. Herman United States 27 874 1.2× 724 1.4× 374 1.1× 393 1.2× 140 0.4× 68 3.3k
Ellen F. Heineman United States 31 429 0.6× 427 0.8× 140 0.4× 899 2.8× 667 2.1× 49 3.2k
Gulshan Ara United States 33 456 0.6× 1.2k 2.3× 141 0.4× 388 1.2× 390 1.2× 156 3.4k
Ashraful Hoque United States 27 556 0.8× 767 1.5× 118 0.3× 558 1.8× 618 2.0× 64 2.2k
Angéla Sutton France 37 591 0.8× 1.5k 3.0× 632 1.9× 366 1.2× 383 1.2× 93 4.3k
Pierluigi Cocco Italy 27 454 0.6× 303 0.6× 433 1.3× 526 1.7× 400 1.3× 99 2.5k
Mark J. Roth United States 35 760 1.1× 1.9k 3.8× 280 0.8× 633 2.0× 775 2.5× 90 4.2k
Denise Riedel Lewis United States 23 1.2k 1.6× 527 1.0× 198 0.6× 688 2.2× 352 1.1× 39 3.4k
Chen Yuan China 31 851 1.2× 930 1.8× 241 0.7× 519 1.6× 540 1.7× 121 3.3k

Countries citing papers authored by D Belpomme

Since Specialization
Citations

This map shows the geographic impact of D Belpomme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D Belpomme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D Belpomme more than expected).

Fields of papers citing papers by D Belpomme

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D Belpomme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D Belpomme. The network helps show where D Belpomme may publish in the future.

Co-authorship network of co-authors of D Belpomme

This figure shows the co-authorship network connecting the top 25 collaborators of D Belpomme. A scholar is included among the top collaborators of D Belpomme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D Belpomme. D Belpomme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Belpomme, D, et al.. (2024). Free Methylglyoxal as a Metabolic New Biomarker of Tumor Cell Proliferation in Cancers. Cancers. 16(23). 3922–3922. 1 indexed citations
2.
Belpomme, D & Philippe Irigaray. (2022). Why electrohypersensitivity and related symptoms are caused by non-ionizing man-made electromagnetic fields: An overview and medical assessment. Environmental Research. 212(Pt A). 113374–113374. 14 indexed citations
3.
Belpomme, D & Philippe Irigaray. (2016). Replicative random mutations as an unproven cause of cancer: A technical comment. Molecular and Clinical Oncology. 4(4). 497–499. 2 indexed citations
4.
Irigaray, Philippe, Stéphanie Lacomme, L. Méjean, & D Belpomme. (2009). Ex vivo study of incorporation into adipocytes and lipolysis-inhibition effect of polycyclic aromatic hydrocarbons. Toxicology Letters. 187(1). 35–39. 20 indexed citations
5.
6.
Belpomme, D, Philippe Irigaray, Lennart Hardell, et al.. (2007). The multitude and diversity of environmental carcinogens. Environmental Research. 105(3). 414–429. 187 indexed citations
7.
Irigaray, Philippe, J.A. Newby, Richard Clapp, et al.. (2007). Lifestyle-related factors and environmental agents causing cancer: An overview. Biomedicine & Pharmacotherapy. 61(10). 640–658. 239 indexed citations
8.
Belpomme, D, Philippe Irigaray, A J Sasco, et al.. (2007). The growing incidence of cancer: Role of lifestyle and screening detection (Review). International Journal of Oncology. 30(5). 1037–49. 76 indexed citations
9.
Irigaray, Philippe, J.A. Newby, Stéphanie Lacomme, & D Belpomme. (2007). Overweight/obesity and cancer genesis: More than a biological link. Biomedicine & Pharmacotherapy. 61(10). 665–678. 70 indexed citations
10.
11.
Kemp, Graham J., Peter S. Rose, John R. Lurain, et al.. (1996). Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.. Journal of Clinical Oncology. 14(7). 2101–2112. 365 indexed citations
12.
Venturini, Letizia, Gino Ronco, Pierre Villa, et al.. (1994). Selective Induction of Apoptosis in Myeloid Leukemic Cell Lines by Monoacetone Glucose-3 Butyrate. Biochemical and Biophysical Research Communications. 201(1). 266–283. 25 indexed citations
13.
Venturini, Letizia, et al.. (1993). Butyric Acid and Its Monosaccharide Ester Induce Apoptosis in the HL-60 Cell Line. Biochemical and Biophysical Research Communications. 195(1). 31–38. 58 indexed citations
14.
Étiemble, Jeanne, J. F. Bernard, C. Picat, D Belpomme, & Pierre Boivin. (1979). Red Blood Cell Enzyme Abnormalities in Patients Treated with Chemotherapy. British Journal of Haematology. 42(3). 391–398. 19 indexed citations
15.
Mathé, G, J. L. Misset, F. de Vassal, et al.. (1978). Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.. PubMed. 62(5). 805–9. 47 indexed citations
16.
Jl, Misset, Matthew J. Hayat, J. Gouveia, et al.. (1978). [Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 7(7). 525–8. 2 indexed citations
17.
Amiel, Jeanne, L Schwarzenberg, P Pouillart, et al.. (1975). Immunothérapie active des leucémies aiguës et des lymphosarcomes leucémiques. Bilar de 10 ans-Etude de 200 cas. ˜La œNouvelle presse médicale. 4(18). 3 indexed citations
18.
Mathé, G, D Belpomme, D Dantchev, & P Pouillart. (1975). Progress in the classification of lymphoid and/or monocytoid leukemias and of lympho and reticulosarcomas (non-Hodgkin's lymphomas).. PubMed. 22(3). 177–85. 16 indexed citations
19.
Belpomme, D, et al.. (1975). [Recent progress made in the classification of lymphoid and monocytoid leukemias and of lympho- and reticulo-sarcomas].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 126(8-9). 523–34.
20.
Jl, Misset, P Pouillart, Amiel Jl, et al.. (1975). [Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].. PubMed. 4(44). 3117–20. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. K. McLaughlin Breakdown of academic impact, for papers by Eugene H. Herman Breakdown of academic impact, for papers by Ellen F. Heineman Breakdown of academic impact, for papers by Gulshan Ara Breakdown of academic impact, for papers by Ashraful Hoque Breakdown of academic impact, for papers by Angéla Sutton Breakdown of academic impact, for papers by Pierluigi Cocco Breakdown of academic impact, for papers by Mark J. Roth Breakdown of academic impact, for papers by Denise Riedel Lewis Breakdown of academic impact, for papers by Chen Yuan
Rankless by CCL
2026